Table 2.
Characteristics of Phase 2/3 and Phase 3 Trials (N=54)
| Trials | Median enrollment per trial | Overall planned enrollment | |
|---|---|---|---|
| Top ten study treatment arm categories | |||
| Antiviral | 10 | 782 | 23147 |
| Monoclonal antibodies | 13 | 450 | 16070 |
| Chloroquine/hydroxychloroquine | 9 | 500 | 9481 |
| Colchicine | 1 | 6000 | 6000 |
| Antibiotic | 5 | 600 | 5365 |
| Anticoagulation | 4 | 762 | 4832 |
| ACE inhibitor | 2 | 2250 | 4500 |
| Polyclonal antibodies | 5 | 600 | 3720 |
| Other | 5 | 525 | 2919 |
| Small molecule immunomodulators | 7 | 358 | 2284 |
| Primary study outcome | |||
| Severity scale | 23 | 450 | 32,197 |
| Composite of mortality or ventilation | 10 | 500 | 6,312 |
| Mortality | 6 | 440 | 3,393 |
| Composite of mortality or hospitalization | 4 | 1050 | 8,500 |
| Hospitalization | 3 | 2271 | 13,821 |
| Composite of mortality, oxygen, ventilation | 3 | 525 | 1,525 |
| Other | 3 | 500 | 2,812 |
| Oxygen | 3 | 250 | 682 |
| Ventilation | 2 | 390 | 779 |
| Composite of oxygen or ventilation | 1 | 573 | 573 |
| Viral load | 1 | 58 | 58 |
| WHO ordinal scale | 1 | 220 | 220 |